Summary MHC class I antigens are intimately involved in intercellular communication, and recognition by cytotoxic T cells. Thus tumour cells that fail to express them may be at a growth or metastatic advantage. A series of ten colorectal and ten breast carcinomas, and their respective lymph node metastases, were examined immunohistologically using monoclonal antibodies (mAb) against both monomorphic and A2 polymorphic determinants, and beta-2-microglobulin (beta 2m). Four (Benacerraf, 1981; Linsk & Goodenow, 1986; Schwartz, 1982) . The class I MHC molecule consists of three alpha regimes, covalently linked to beta-2-microglobulin (beta 2m), which are encoded by separate genes, and linked prior to expression at the cell membrane (Ploegh et al., 1981; Arce-Gomez, 1978 (Eisenbach et al., 1983; 1985) . Studies on the expression of human MHC class I antigens in primary vs metastatic tumour are limited; for example malignant melanoma, digestive tract, and laryngeal tumours (Ruiz-Cabello et al., 1989; Esteban et al., 1989) . In these studies, both increased and decreased expression of monomorphic determinants of HLA class I was observed in the metastases compared with their primaries. In the present study we have used mAbs to evaluate a series of human primary colon and breast carcinomas, and their lymph node metastases, for the expression of monomorphic and polymorphic HLA class I determinants. Normal colon mucosa and, where possible, colon adenomas and liver metastases were included in the study. Many of the primary tumours at both sites showed reduced staining for monomorphic and polymorphic HLA class I determinants; metastases showed both greater and lesser degrees of loss of HLA expression when compared with their primary. 
MHC Class I and II genes encode for proteins which are intimately involved in intercellular communications, and establishing self identity for controlling immunological responses. While MHC class II antigens (in man referred to as HLA-DR, DP or DQ) have limited expression on cells of the immune system, MHC Class I antigens are found on all somatic cells as heterodimeric molecules (Benacerraf, 1981; Linsk & Goodenow, 1986; Schwartz, 1982) . The class I MHC molecule consists of three alpha regimes, covalently linked to beta-2-microglobulin (beta 2m), which are encoded by separate genes, and linked prior to expression at the cell membrane (Ploegh et al., 1981; Arce-Gomez, 1978) . T cell recognition of antigen at the cell membrane is restricted to cells expressing compatible HLA determinants (Zinkernagel & Doherty, 1979) . Similarly, immunological recognition of tumour antigens by cytotoxic T lymphocytes (CTL) is restricted to histocompatible cell types. Failure to express HLA class I, or the expression of inappropriate or altered HLA components on cells, is a possible mechanism whereby tumour cells may escape destruction by antigen specific CTL. Several studies have now shown that many human tumours fail to express antigens recognised by monoclonal antibodies (mAbs) specific for the monomorphic sites of HLA class I molecules (Masucci et al., 1987; Smith et al., 1988; Broker et al., 1984; Lopez-Nevot et al., 1989; Momburg et al., 1986; Momburg & Koch, 1989; Muller & Stutte, 1988; Natali et al., 1983; Perez et al., 1986) . Furthermore, some primary human colon carcinomas fail to express HLA class I polymorphic regions (Rees et al., 1988; Momburg & Koch, 1989) ; the absence of these haplotypes may also be significant.
Experimental studies in murine tumours have shown that the expression of H2 D and K products is important, and in some ways is linked with metastatic potential. With these immunogenic tumours, those with a high level of MHC antigen expression show low metastatic ability; transfection and subsequent expression of the H2K gene into otherwise highly metastatic H2K-negative tumour cell variants reduces tumour growth, and prevents metastasis (Eisenbach et al., 1983; 1985) . Studies on the expression of human MHC class I antigens in primary vs metastatic tumour are limited; for example malignant melanoma, digestive tract, and laryngeal tumours (Ruiz-Cabello et al., 1989; Esteban et al., 1989) . In these studies, both increased and decreased expression of monomorphic determinants of HLA class I was observed in the metastases compared with their primaries. In the present study we have used mAbs to evaluate a series of human primary colon and breast carcinomas, and their lymph node metastases, for the expression of monomorphic and polymorphic HLA class I determinants. Normal colon mucosa and, where possible, colon adenomas and liver metastases were included in the study. Many of the primary tumours at both sites showed reduced staining for monomorphic and polymorphic HLA All normal tissue stained positively with W6/32 and anti beta 2m mAb, whereas primary tumour was either partly or wholly negative in six out of ten samples stained with W6/32 (Figure 1) , and four out of six stained with anti beta 2m. Polypoid adenomas were uniformly positive with W6/32 or anti beta 2m mAb. Two lymph node metastases expressed less HLA reactivity than their primary tumours (Figure 2 ), while four further lymph node metastases had an increased expression of HLA compared with the primary tumour. Using anti beta 2m mAb two lymph node metastases showed a loss of reactivity compared with their primary tumour, while one metastasis showed an increased expression (Table  II) . Table III shows the results of a similar study using primary tumour and lymph node metastases from a series of ten human breast cancers. In these tissues two primary tumours showed a partial or complete loss of reactivity using W6/32 mAb. Two lymph node metastases had reduced staining with W6/32 when compared with their primary. A more pronounced loss of reactivity was observed using anti beta 2m mAb in both primary and lymph node metastases. With the primary breast carcinomas four tumours showed a complete absence of anti beta 2m staining, and a further four out of the ten demonstrated a partial loss of reactivity. The lymph node metastases showed a complete absence of beta 2m in eight out of ten tumours: with the remaining two samples both the primary tumours were uniformly positive, while their metastases showed only partial expression of beta 2m.
MHC class I HLA A2 polymorphic antigen determinants Eight patients (four colon, four breast carcinomas) were positive for A2, either on tissue typing or by demonstrating 
Discussion
The loss or aberrant expression of HLA class I monomorphic or polymorphic determinants on tumour cells would theoretically allow them to escape cytotoxic attack by lymphocytes mediating antigen specific recognition. Whilst altered expression has been reported in a wide range of human tumours, studies to assess this in relation to metastasis are few. Using mAbs against monomorphic HLA determinants and beta 2m, examinations of melanoma, squamous carcinoma of larynx, and colorectal adenocarcinoma have shown divergence and loss of expression of class I HLA between primary tumours and their metastases Ruiz-Cabello et al., 1989) . There was also correlation between the grade of differentiation and expression amongst the laryngeal carcinomas, with loss in poorly differentiated tumours. In some instances the lack of HLA class I expression is due to a loss of gene activity, as shown in a recent study (Momberg & Koch, 1989) which demonstrated the absence of beta 2m protein from human colon carcinomas to be associated with loss of messenger RNA.
In a previous report we have documented the loss of both monomorphic and polymorphic HLA class I determinants in human colon carcinoma (Rees et al., 1988) ; in several cases primary tumours that stained with mAb W6/32 failed to stain with a mAb specific for the appropriate haplotype (A2 or Bw4). The presence study evaluates further the expression of HLA class I molecules in primary and metastatic deposits from individual patients with colon or breast carcinoma. Although partial or total loss of reactivity was observed in tissue containing tumour, no consistent pattern could be established between the primary and metastatic tumour in individual patients. Both an increase and a decrease in HLA expression was seen in colon carcinoma lymph node deposits when compared with their primaries; the one liver metastasis showed a decrease, and the staining of colon polypoid adenomas was identical to normal mucosa. With breast carcinomas, although there was some loss of reactivity in the metastases for HLA class I monomorphic antigen (W6/32 staining), a decrease in staining with anti-beta 2m was seen. Though this was a striking feature of the breast carcinomas, it is probably not a true indication of decreased beta 2m, in view of the non-covalent linkage between it and the rest of the class I MHC molecule identified by W6/32. Immunohistology is at best only semi-quantitative, and the reduced staining may reflect a lower affinity for the antibody. The lack of expression of HLA A2 polymorphic antigen determinants was confirmed in most of the relevant colon carcinomas; while some of the breast metastases showed loss compared with their primaries. Although only eight cases were examined, these observations provide further evidence which suggests that loss of class I antigenic determinants is preferentially associated with metastasis. The cases in this study have been selected because metastases were available; the expression of HLA antigens in the primary tumours has not been compared with its expression in tumours of similar size and grade without known metastases -features known to correlate with clinical outcome (and thus metastasis) in breast carcinoma (Haybittle et al., 1982) . In a study by Ruiz-Cabello et al. (1989) , where class I expression was studied in colon, melanoma and epidermoid tumours, divergence of expression of class I was seen between primary tumours and their autologous metastases. Of the six cases reported, only two metastases showed a decrease in the intensity of staining with W6/32 monoclonal antibody compared with the primary tumour. A further report by this group reported an apparent decrease in the number of tumour cells expressing monomorphic HLA antigens in right colon carcinoma metastases.
In colorectal, gastric and laryngeal carcinomas a selective loss of HLA-B isotype determinants occurred in tumours previously classified as HLA positive . Although differences in HLA expression between tumour types is observed, a consensus of opinion supports the view that both monomorphic and polymorphic HLA determinants are decreased in metastatic tumour deposits compared with its autologous primary tumour. In spite of the relationship between HLA expression and immunity, it may well be that its loss in tumours with an enhanced metastatic phenotype is a reflection of biological events other than those of an immunological nature. For example, they interact with some growth factor receptors and cytoskeletal proteins, and are capable of modulating secondary and tertiary cell signalling pathways (Haliotis et al., 1990) ; this may confer a metastatic advantage.
